Recruiting

Umbilical Cord Blood Transplantation

Sponsor:

University of Rochester

Code:

NCT03016806

Conditions

Acute Leukemia

Immune Deficiency Disorder

Congenital Hematological Disorder

Metabolism Disorder

Aplastic Anemia

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Total Body Irradiation 1200 cGy

Total Body Irradiation 200 cGy

Cyclophosphamide

Mesna

Cord Blood Infusion

Study Details

Brief summary:

This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated donor fails. Another purpose will be to document the rate of disease-free survival and the rate of relapse (a return of your disease or syndrome) as well as the incidence and severity of graft versus host disease (GvHD) following cord blood stem cell transplantation. GvHD is a complication of stem cell transplants in which white blood cells from the transplanted tissue (graft) attack the transplant recipient's body (host).

Conditions

Acute Leukemia

Immune Deficiency Disorder

Congenital Hematological Disorder

Metabolism Disorder

Aplastic Anemia

Study ID

NCT03016806

Start date

Jun, 2015

Status verified date

Oct, 2025

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Appropriate diagnosis: Patients must have a disease or syndrome amenable to therapy with hematopoietic stem cell transplantation. Diagnoses include, but are not limited to:
  • Congenital and Other Non-malignant Disorders:
  • Immunodeficiency disorders (e.g. Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome)
  • Congenital hematopoietic stem cell defects (e.g. Chediak-Higashi Syndrome, Congenital Osteopetrosis, Osteogenesis Imperfecta)
  • Metabolic disorders (e.g. Hurler's Syndrome)
  • Severe aplastic anemia
  • High-Risk Leukemia:
  • Acute Myelogenous Leukemia
  • Refractory to standard induction therapy (more than 1 cycle required to achieve remission)

  • Recurrent (in CR ≥ 2)
  • Treatment-related AML or MDS
  • Evolved from myelodysplastic syndrome
  • Presence of FLT3 abnormalities
  • FAB M6 or M7
  • Adverse cytogenetics
  • Myelodysplastic Syndrome
  • Acute Lymphoblastic Leukemia including T lymphoblastic leukemia:
  • Refractory to standard induction therapy (time to CR >4 weeks)
  • Recurrent (in CR ≥ 2)
  • WBC count >30,000/mcL at diagnosis
  • Age >30 at diagnosis
  • Adverse cytogenetics, such as t(9:22), t(1:19), t(4:11), and other MLL rearrangements.
  • Chronic Myelogenous Leukemia in accelerated phase or blast crisis
  • Biphenotypic or undifferentiated leukemia
  • Burkitt's leukemia or lymphoma
  • Lymphoma:
  • Large cell, Mantle cell, Hodgkin lymphoma refractory or recurrent, chemo-sensitive, and ineligible for an autologous stem cell transplant or previously treated with autologous SCT
  • Marginal zone or follicular lymphoma that is progressive after at least two prior therapies
  • Multiple Myeloma, recurrent following high-dose therapy and autologous SCT or ineligible for an autologous HSCT
  • Solid tumors, with efficacy of allogeneic HSCT demonstrated for the specific disease and disease status
  • Adequate organ function:
  • Cardiac - LVEF >45%, or shortening fraction >25%, Absence of congestive heart failure or conduction disturbances with high risk for sudden death
  • Pulmonary - DLCO (corrected for hemoglobin), FEV1 and FVC ≥ 50% predicted;
  • Renal - serum Cr < 1.5 times the upper limit of normal for age or GFR ≥ 50 ml/min/1.73m2
  • Hepatic - total bilirubin level < 2 times the upper limit of normal (except for patients with Gilbert's syndrome or hemolysis); if the primary disease process is causal, this criterion will be reconsidered. ALT, AST, and Alkaline phosphatase ≤ 5 times upper limit of normal.
  • Performance Status Karnofsky or Lansky score ≥ 70%.
  • Informed Consent must be obtained prior to initiating conditioning therapy.
  • Receipt of viable cord blood product(s), single or dual, must be confirmed with the stem cell processing laboratory prior to initiating conditioning therapy.

Exclusion Criteria:

  • Availability of 10/10 or 9/10 HLA-matched related or unrelated donor within a reasonable timeframe dictated by the clinical urgency of the transplant
  • Autologous HSCT < 6 months prior to proposed UCB transplant
  • Pregnant or breast feeding
  • Current uncontrolled infection
  • Evidence of HIV infection or positive HIV serology

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

Full Intensity, TBI-based Conditioning

Full Intensity TBI-based Conditioning Total Body Irradiation 1200 cGy in fractions of 150 cGy days -8 or -7 to -4 Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses \[to be completed 24 hours after final Cyclophosphamide dose\] followed by Cord Blood Infusion Other names: TBI/Cy

Full Intensity, Chemo-based Conditioning

Full Intensity, Chemotherapy Conditioning Busulfan days -7 to -4 Recipients <5 years - 1 mg/kg/dose x 16 doses every 6 hours Recipients >/= 5 years - 0.8 mg/kg/dose x 16 doses every 6 hours Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses \[to be completed 24 hours after final Cyclophosphamide dose\] followed by Cord Blood Infusion Other names: Bu/Cy

Reduced Intensity Chemotherapy

Reduced Intensity Chemotherapy Fludarabine 30 mg/m2/day x 5 doses days -6 to -2 Melphalan 140 mg/m2/day x 1 dose day -2 Cord Blood Infusion Other names: Flu/Mel

Non-Myeloablative Conditioning

Fludarabine 40 mg/m2/day x 5 doses days -6 to -2 Cyclophosphamide 50 mg/kg/day x 1 dose day -6 Mesna 50 mg/kg/day with 20% loading dose with Cyclophosphamide dose followed by continuous infusion over 24 hours x 1 dose \[to be completed 24 hours after Cyclophosphamide dose\] Total Body Irradiation 200 cGy in a single fraction day -1 Cord Blood Infusion Other names: Flu/Cy/TBI

Interventions

Total Body Irradiation 1200 cGy

Total Body Irradiation 1200 cGy in 8 fractions

Total Body Irradiation 200 cGy

Total Body Irradiation 200 cGy in one fraction

Cyclophosphamide

50 mg/kg or 60 mg/kg

Mesna

50 mg/kg or 60 mg/kg plus 10% loading dose

Cord Blood Infusion

Intravenous infusion of cord blood stem cells

Busulfan

0.8 mg/kg x 16 doses

Fludarabine

30 mg/m2/day x 5 or 40 mg/m2/day x 5

Melphalan

140 mg/m2

Primary outcome measure

  • Engraftment of ANC and Platelets [ Time Frame: 42 days following the infusion of stem cells for ANC [If engraftment of ANC does not occur within 42 days, a subsequent transplant will be performed if a donor is available.] ]

Central Contacts and Locations

Central contacts

Omar Aljitawi, MD

585-275-4099omar_aljitawi@urmc.rochester.edu

Locations

Wilmot Cancer Institute

Recruiting

Rochester, New York, United States, 14642

Contacts

Omar Aljitawi, MD

585-275-4099omar_aljitawi@urmc.rochester.edu

More Information

Sponsor

University of Rochester

Last update posted

Oct 10, 2025

Last verified

Oct, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Rochester on 2025-10-10.